Chen Even - DIASORIN President
| 34D Stock | EUR 101.15 1.25 1.22% |
President
Dr. Chen Manachem Even serves as Executive Director, Chief Commercial Officer of Diasorin S.p.A. He is Chief Commercial Officer since January 1, 2016. He was in the Company Board of Directors since March 26, 2007. Additionally, he serves at Glycominds Ltd., CID Investments Srl, and others. He graduated in Information Science in 1989. In 1995, he received a Doctorate of Medicine degree in Virology and Immunology Research from the School of Medicine of University of Minnesota. He serves as Director of Glycominds LTD, DiaSorin Ltd, CID SpA, DiaSorin SANV, DiaSorin INC, Diasorin Ltd, DiaSorin Iberia SA, DiaSorin Mexico SA de CV, DiaSorin Australia Pty, DiaSorin Diagnostics Ireland Limited, DiaSorin I.N.UK and DiaSorin Ireland Limited. since 2016.
| Age | 56 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
DIASORIN Leadership Team
Elected by the shareholders, the DIASORIN's board of directors comprises two types of representatives: DIASORIN inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DIASORIN. The board's role is to monitor DIASORIN's management team and ensure that shareholders' interests are well served. DIASORIN's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DIASORIN's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Francesca Pasinelli, Independent Director | ||
| Michele Denegri, Non-Executive Deputy Chairman of the Board | ||
| Giancarlo Boschetti, Non-Executive Director | ||
| Piergiorgio Pedron, Senior Corporate VP and Chief Financial Officer | ||
| Tullia Todros, Independent Director | ||
| Elisa Corghi, Independent Director | ||
| Stefano Ronchi, Senior Corporate Vice President - Human Resources | ||
| Riccardo Fava, External Relations Director, Head of Investor Relations and Media | ||
| Giuseppe Alessandria, Lead Independent Director | ||
| Roberta Somati, Independent Director | ||
| Stefano Altara, Non-Executive Director | ||
| John Gerace, President DiaSorin Molecular LLC | ||
| Luca Melindo, Non-Executive Director | ||
| Franco Moscetti, Independent Director | ||
| Gustavo Denegri, Non-Executive Chairman of the Board | ||
| Carlo Rosa, Chief Executive Officer, Executive Director, General Manager | ||
| Fiorella Altruda, Independent Director | ||
| Monica Tardivo, Independent Director | ||
| Ugo Gay, Senior Corporate Vice President - Industrial Operations | ||
| Chen Even, Senior Corporate Vice President - Commercial Operations and Executive Director |
DIASORIN Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DIASORIN a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 8.21 B | |||
| Price To Book | 4.51 X | |||
| Price To Sales | 5.18 X | |||
| Revenue | 1.24 B | |||
| EBITDA | 517.3 M | |||
| Net Income | 310.97 M | |||
| Total Debt | 1.23 B | |||
| Cash Flow From Operations | 400.66 M | |||
| Price To Earnings To Growth | 176.54 X | |||
| Number Of Employees | 29 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in DIASORIN Stock
DIASORIN financial ratios help investors to determine whether DIASORIN Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DIASORIN with respect to the benefits of owning DIASORIN security.